---
title: "Neurocrine (NBIX) Gets a Buy from Stifel Nicolaus"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285372122.md"
description: "In a recent report, Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurocrine (NBIX) with a price target of $188.00. Matteis, who has a 14.4% average return and a 50.51% success rate, also covers other healthcare stocks. Additionally, Canaccord Genuity's Sumant Kulkarni also issued a Buy rating for Neurocrine, while Morgan Stanley reiterated a Hold rating on the same day."
datetime: "2026-05-06T11:46:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285372122.md)
  - [en](https://longbridge.com/en/news/285372122.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285372122.md)
---

# Neurocrine (NBIX) Gets a Buy from Stifel Nicolaus

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Neurocrine, with a price target of $188.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Matteis covers the Healthcare sector, focusing on stocks such as Xenon, Vertex Pharmaceuticals, and Ionis Pharmaceuticals. According to TipRanks, Matteis has an average return of 14.4% and a 50.51% success rate on recommended stocks.

In addition to Stifel Nicolaus, Neurocrine also received a Buy from Canaccord Genuity’s Sumant Kulkarni in a report issued today. However, on the same day, Morgan Stanley reiterated a Hold rating on Neurocrine (NASDAQ: NBIX).

### Related Stocks

- [NBIX.US](https://longbridge.com/en/quote/NBIX.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [XENE.US](https://longbridge.com/en/quote/XENE.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Neurocrine Biosciences (NBIX) Valuation Check As New INGREZZA Real World Data Draws Fresh Attention](https://longbridge.com/en/news/287134643.md)
- [Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors](https://longbridge.com/en/news/286946226.md)
- [Stifel Just Raised Its Price Target on Palo Alto Networks. Here's Why.](https://longbridge.com/en/news/287118503.md)
- [Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics | NBIX Stock News](https://longbridge.com/en/news/286773551.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)